Literature DB >> 3366451

The ratio of prostate chips with cancer: a new measure of tumor extent and its relationship to grade and prognosis.

P Humphrey1, R T Vollmer.   

Abstract

The ratio of chips with cancer to the total number of chips was studied in 118 patients with prostate cancer who underwent transurethral prostatectomy. We found that this ratio is a prognosticator closely associated to the stage of tumor (local or extensive) and to the chance of death from prostate cancer. Stage, the ratio of positive chips and the Gleason histologic score are all closely tied one to another, and it is unclear from this initial study whether these variables provide independent or additive prognostic information. Nevertheless, the ratio of positive chips shows far better interobserver agreement than does the Gleason score, and in patients with the most common predominant score of three, it can separate most of those with localized disease from most of those with extensive disease. Thus the ratio shows promise as a reliable predictor of stage of disease and of long-term failure, and hence it may help in the choice of patients for curative surgery.

Entities:  

Mesh:

Year:  1988        PMID: 3366451     DOI: 10.1016/s0046-8177(88)80490-8

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent.

Authors:  Ramzi Rajab; Gabrielle Fisher; Michael W Kattan; Christopher S Foster; Henrik Møller; Tim Oliver; Victor Reuter; Peter T Scardino; Jack Cuzick; Daniel M Berney
Journal:  Mod Pathol       Date:  2010-09-10       Impact factor: 7.842

2.  Tumor extent in radical prostatectomy specimens: is it an independent prognostic factor for biochemical (PSA) progression following surgery?

Authors:  Athanase Billis; Luciana Meirelles; Leandro L Freitas; Luis A Magna; Ubirajara Ferreira; Leonardo O Reis
Journal:  Int Urol Nephrol       Date:  2010-08-10       Impact factor: 2.370

3.  Diagnosis, prognosis and management of incidentally found prostate cancer.

Authors:  P J Davidson
Journal:  Urol Res       Date:  1993-01

4.  Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort.

Authors:  Lorelei A Mucci; Yudi Pawitan; Francesca Demichelis; Katja Fall; Jennifer R Stark; Hans-Olov Adami; Swen-Olof Andersson; Ove Andrén; Anna Eisenstein; Lars Holmberg; Wei Huang; Philip W Kantoff; Robert Kim; Sven Perner; Meir J Stampfer; Jan-Erik Johansson; Mark A Rubin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-06-26       Impact factor: 4.254

5.  Prostate cancer trends in Canada: rising incidence or increased detection?

Authors:  I G Levy; L Gibbons; J P Collins; D G Perkins; Y Mao
Journal:  CMAJ       Date:  1993-09-01       Impact factor: 8.262

6.  MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden.

Authors:  O Andrén; K Fall; S-O Andersson; M A Rubin; T A Bismar; M Karlsson; J-E Johansson; L A Mucci
Journal:  Br J Cancer       Date:  2007-08-28       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.